WHO has listed obesity as a disease condition in its International Classification of Disease since 1979 and has assigned obesity a specific ICD-9, clinical modification code of #278.00, and morbid obesity, code #278.01. About 95% of those conservatively treated for morbid obesity will remain at the same weight or even gain weight during 5 years of follow-up. In 1991 an NIH Consensus Conference Panel convened and recommended that morbidly obese patients be offered an operative treatment for their disease. The weight loss mechanism of the bariatric operations is not clear, but the presumed effects are gastric restriction of food intake, malabsorption of the nutrients achieved by intestinal bypass, and secretion of different neuropeptides, that cause depression of the appetite and change in the metabolic rate. Restrictive operations are considered simpler and safer in terms of surgical performance and short term risks, but their efficacy is inferior to the malabsorptive ones. The latter are larger in regard to surgical extent, may cause more metabolic derangements, but produce more solid and long-lasting weight loss. The operation should be tailored to the candidate taking into consideration sex, age, health-related conditions, medications that are being taken, eating habits, and risks and benefits of every specific procedure. It is advisable that a bariatric surgery candidate undergo a thorough preoperative evaluation by a multidisciplinary team including a surgeon, a dietician, a psychology specialist, an internist or an endocrinologist, and other subspecialties as needed. A bariatric patient should maintain a life-long follow-up.

Download full-text PDF

Source

Publication Analysis

Top Keywords

morbid obesity
8
weight loss
8
[surgical treatment
4
treatment morbid
4
morbid obesity]
4
obesity] listed
4
obesity
4
listed obesity
4
obesity disease
4
disease condition
4

Similar Publications

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

GloNeuro Academy, Noida, Uttar Pradesh, India.

Background: Obesity and ageing individually pose significant challenges to global public health, leading to preventable deaths. With an increasing geriatric population due to improved medical interventions, the intersection of these health issues becomes a critical concern worldwide. Both developed and developing countries grapple with the consequences of obesity, a major risk factor for various conditions like cardiovascular diseases, hypertension, type 2 diabetes, dementia, and neuropsychiatric diseases.

View Article and Find Full Text PDF

Introduction: Very low-calorie diets with hospitalization have demonstrated promise as a viable therapeutic option for severe obesity and its associated comorbidities. However, large studies providing a comprehensive longitudinal observation of patients undergoing this therapy are lacking. We evaluated the effectiveness of treating severe obesity in hospitalized patients, using very low-calorie diets and clinical support to develop lifestyle changes.

View Article and Find Full Text PDF

Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery.

Metabolism

December 2024

Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Malaga, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto Salud Carlos III, Madrid, Spain.

Background: The successful weight loss following bariatric surgery is not achieved in all patients with morbid obesity (MO). This study aims to determine whether a serum miRNA profile can predict this outcome.

Design: Thirty-three patients with MO were classified in "Good Responders" (GR, percentage of excess weight loss (%EWL) ≥ 50 %) or "Non-Responders" (NR, %EWL < 50 %) according to the %EWL 5-8 year following bariatric surgery.

View Article and Find Full Text PDF

Obesity is a recognized risk factor for venous thromboembolism (VTE), associated with distinct challenges in managing anticoagulation therapy. There is still limited evidence regarding the impact of extreme body weight on the pharmacokinetics, pharmacodynamics, efficacy, and safety of various anticoagulant medications. To our knowledge, this is the first comprehensive review to address both prophylactic and therapeutic anticoagulant dosages specifically for managing VTE in patients with a body mass index (BMI) ≥40 kg/m or weight ≥120 kg.

View Article and Find Full Text PDF

Background: Due to the global growth of its prevalence and its impact on patient health, obesity is considered a near-epidemic condition by the World Health Organization (WHO). Its overall prevalence has now reached 17 % in France. The impact of obesity is also a concern for pregnant women, due to the risk of maternal and fetal complications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!